Retrospective longitudinal data (2013–2024) from six immunotherapy-naive MuSK-MG patients yielded 103 observations linking MuSK antibody levels to MG-ADL using generalized linear mixed-effects ...
InvestorsHub on MSN
Johnson & Johnson’s IMAAVY demonstrates durable disease control in myasthenia gravis
Johnson & Johnson (NYSE:JNJ) has reported new data from its Phase 3 Vivacity-MG3 trial showing that its therapy IMAAVY ...
Edrophonium achieved 83.5% sensitivity and 87.7% specificity across 182 myasthenia gravis cases and 324 controls. Test positivity remained similar across postsynaptic acetylcholine receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results